We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novo Nordisk Presents Positive Phase III Results from Semaglutide and Xultophy
Novo Nordisk Presents Positive Phase III Results from Semaglutide and Xultophy
Novo Nordisk presented two separate Phase III studies in type 2 diabetes—evaluating semaglutide and Xultophy—at the annual meeting of the European Association for the Study of Diabetes.